BTW: Its otherwise the same as in PA'154 (the patent application) except for there is an R-squared = 0.38 and p=0.04 at ODAC and a Spearman r =0.76 p=0.0086 in Figure 7 of PA'154. )
How does the p value become a lot more significant(p=0.0086 (patent application figure 7) vs p=0.04 (ODAC slide cc-32) when the diagrams have the same 11 (visible) data points in the same spacial pattern?
----- Stepping back - why the focus on this 11 data points - why does it matter so much? - its where the IL2Ralpha part of the two part potency assay is investigated in actual patients in the GVHD001 which is the only potential adequate and well controlled study (the FDA is supposed to have at least one for a BLA (diversion I've been reading LearningEachDays linked reference to a product that was controversially approved by Janet Woodcott for Muscular Dystrophy (I think its a case of politcs trumping science in the FDA) - and I don't think its (GvHD-001) that because of the confounding and too small data set.
CYP Price at posting:
26.0¢ Sentiment: Hold Disclosure: Held
(20min delay)